No.1 Healthcare & Pharma Industry Magazine for Middle East & Africa
USA — Evusheld, a preventative monoclonal antibody treatment for COVID-19, has lost its emergency use authorization in the United States because it is unlikely to be effective against the coronavirus…
Read More
USA— AstraZeneca has struck a deal to buy US-based biopharmaceutical firm CinCor Pharma Inc for up to US$1.8 billion to strengthen its pipeline of heart and kidney drugs and grow…
Read More
USA— According to a recent Food and Drug Administration (FDA) communication, Lumoxiti for injection will be permanently discontinued in the US market by August 31, 2023. The FDA approved Lumoxiti,…
Read More
AFRICA – Pharma giants AstraZeneca and Pfizer have reiterated their focus on sustainability with their on-going carbon footprint funding. AstraZeneca has set scope 1 and 2 target featuring carbon emissions…
Read More
UAE – Biopharma giant AstraZeneca and G42 Healthcare, an AI-powered healthcare company, have teamed up to locally manufacture innovative drugs in the Emirate of Abu Dhabi. The strategic partnership deal…
Read More
AFRICA – AstraZeneca is set to establish a new liver cancer research partnership in countries in Africa to accelerate improved understanding and care for a form of liver cancer. In…
Read More
INDIA – AstraZeneca Pharma India Ltd. has appointed Dr. Sanjeev Panchal as Country President and Managing Director for a three-year term beginning January 1, 2023. He succeeds Gagandeep Singh Bedi,…
Read More
AFRICA – AstraZeneca, a multinational pharmaceutical and biotechnology company, has announced a planned expansion of its access to healthcare programme, Healthy Heart Africa (HHA), to 10 new countries, starting in…
Read More
UNITED KINGDOM — AstraZeneca is set to acquire biotechnology company Neogene Therapeutics for up to US$320 million as it seeks to build its pipeline of cell-based cancer treatments. Though AstraZeneca’s…
Read More
UNITED KINGDOM — C4X Discovery Holdings (C4XD), based in Manchester, has signed an exclusive global licensing agreement worth up to US$402 million with pharmaceutical giant AstraZeneca. C4XD’s NRF2 Activator program…
Read More